The mix doesn't come with tested instructions
The usual GLOW lineup has three ingredients: TB-500, GHK-Cu and BPC-157. No controlled human trial has established how to use that combination. A commonly repeated amount isn't the same as a tested regimen.
A ratio tells you how much of one ingredient there is compared with another. It doesn't tell you what amount is safe for a person. Nor does it settle how often to use a preparation or for how long.
A clinician has to consider whether treatment makes sense at all. A dosage search can't account for your health history or make that decision.
What one small study actually used
Intravenous means into a vein. In Lee and Burgess's BPC-157 intravenous safety pilot, researchers gave two healthy adults 10 mg on the first day and 20 mg on the second. They reported no observed adverse events, meaning health problems during the study, or measurable changes in the blood markers they checked.
The number that matters most here may be two: the entire study involved two people. Both had received BPC-157 into a vein before this pilot, and there was no comparison group. That's far too small a group to show how often less common problems might happen. It also wasn't a study of whether the treatment helped a health concern.
The pilot tested BPC-157 alone, not GLOW. Its amounts don't supply instructions for the blend or for another route, such as an injection under the skin. A review of BPC-157 still called for well-designed human trials.
Other ingredient studies don't fill the gap
The GHK-Cu collagen experiment used cells in a dish. A concentration in the liquid around those cells isn't a dose for a whole person. The experiment didn't test the blend.
The human thymosin beta-4 study used the full protein, not the smaller TB-500 fragment. Its results can't provide instructions for a different substance. Putting three ingredients together doesn't fix either mismatch.
We also lack research showing how GLOW's ingredients move through and leave the body together. Mixing them doesn't establish compatible timing or long-term safety. A neat schedule can make those unknowns easy to miss.
Questions that leave room for an honest answer
A care conversation can start with the exact preparation and the reason it's being considered. What research supports that use? What is unknown, and what other options fit the concern?
Those questions leave room for a decision against treatment. The effects page covers safety concerns, while the research page explains why ingredient findings don't establish a GLOW treatment plan.